Trial Profile

A Multicenter, Pilot Study to Evaluate Next-Dose Transition From Zolpidem to Lemborexant for the Treatment of Insomnia

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 04 Jun 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

18 Apr 2024 Results assessing the success rate of direct transitioning from Z-drugs to a competitive dual orexin receptor antagonist, lemborexant (LEM), in subjects with insomnia presented at the 76th Annual Meeting of the American Academy of Neurology 2024
22 Apr 2021 Results assessing next-dose transition from zolpidem to lemborexant and safety in subjects with insomnia, presented at the 73rd Annual Meeting of the American Academy of Neurology.
28 Aug 2020 According to an Eisai Inc media release, interim results from this pilot study were presented at the SLEEP 2020 virtual conference, the 34th annual meeting of the Associated Professional Sleep Societies, August 27th-30th, 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com